12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tirasemtiv: Phase IIa data

The double-blind, crossover, U.S. Phase IIa CY 4023 trial in 32 patients with generalized myasthenia gravis showed that single doses of 250 and 500 mg oral tirasemtiv significantly and dose-dependently improved QMG scores vs. placebo at 6 hours post-treatment (0.49-point reduction per 250 mg; p=0.02 for the trend compared to placebo). Cytokinetics said it has not yet reported data comparing each individual dose of tirasemtiv to placebo. According to the...

Read the full 328 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >